Jaguar Health, Inc. (JAGX)
| Market Cap | 166.28M |
| Revenue (ttm) | 9.39M |
| Net Income (ttm) | -38.65M |
| Shares Out | 38.64M |
| EPS (ttm) | -1.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $1.26 |
| Previous Close | $1.30 |
| Change ($) | -0.05 |
| Change (%) | -3.46% |
| Day's Open | 1.25 |
| Day's Range | 1.25 - 1.38 |
| Day's Volume | 3,558,116 |
| 52-Week Range | 0.19 - 4.47 |
Registration link for webcast interview appears below Company premiers Napo EU's new logo and branding, now live on Napoeu.com website SAN FRANCISCO, CA / ACCESSWIRE / April 19, 2021 / Jaguar Health, In...
Merger of Napo EU and Dragon SPAC targeted for mid-2021 Jaguar kicks off educational awareness contest in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication...
SAN FRANCISCO, CA / ACCESSWIRE / April 14, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that an abstract associated with cancer therapy-related diarrhea ("CTD") by Napo Pharmaceuticals, Inc....
Stock purchase price under the agreement increases to $3.00 per share SAN FRANCISCO, CA / ACCESSWIRE / April 8, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Jaguar has entered into an a...
SAN FRANCISCO, CA / ACCESSWIRE / April 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company has promoted Carol Lizak, an accomplished financial execut...
SAN FRANCISCO, CA / ACCESSWIRE / April 2, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that effective March 26, 2021, the Company granted nonstatutory stock optio...
It's easy to dismiss JAGX stock as just another beneficiary of the equity bull market. However, Jaguar Health has made significant strides during the last year.
Jaguar Health (JAGX) stock is heading higher on Thursday following the release of the biopharma company's earnings for the full year of 2020. The post JAGX Stock: 15 Things Giving Jaguar Health Shares a...
Mytesi® net sales and gross sales grew 64% and 148%, respectively, in 2020 compared to 2019 SAN FRANCISCO, CA / ACCESSWIRE / March 31, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company"...
Update regarding March 15, 2021 meeting with European regulatory authority regarding potential Covid-related indication for crofelemer SAN FRANCISCO, CA / ACCESSWIRE / March 30, 2021 / Jaguar Health, In...
New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV SAN FRANCISCO, CA / ACCESSWIRE / March 22, 2021...
Napo EU will serve as the foundation of the Company's efforts to address the growing burden - particularly in Europe - of the inflammatory diarrhea associated with long-hauler syndrome in the post COVID...
No royalty payments due for 36 months Company has started to identify key opinion leader physicians in the US as well as Europe focused on addressing the symptoms - including gastrointestinal distress -...
Continuing Friday's rally, Jaguar Health Inc (NASDAQ: JAGX) stock has surged on Monday as the investors react to the news of its third royalty financing agreement announced on Friday. The company entere...
JAGX stock is on the move today after Jaguar Health announced a plan to secure $5 million of funding. Here's what to know now.
These seven meme stocks have been caught up in the short squeeze, and have grown immensely despite showing little promise from their fundamentals. The post 7 Meme Stocks That Have Retail Traders ‘Stonk-...
JAGX stock has risen dramatically on positive sentiment about the potential for an expanded market for the company's core Mytesi drug. The post Is the Parabolic Rise of JAGX Stock Too Good to Be True?
No royalty payments due for 36 months Planned COVID-related indication in long-hauler patients is the lead focus for crofelemer at Napo EU, the exclusive target of the planned Dragon SPAC, which is purs...
Jaguar Health is doing the right thing while JAGX stock is on the skids. It is falling into support, so there could be relief coming.
Jaguar Health did not have a good February. Down 25% through Feb. 25, it might be time to give up on JAGX stock despite SPAC spinoff.
JAGX stock needs to prove the effectiveness of its drug candidates before investors can consider jumping on its bandwagon. The post Jaguar Health Has Promise, But It's Not a Good Investment Yet appeared...
Jaguar Health Inc (NASDAQ: JAGX) has signed a Memorandum of Understanding (MoU) with the lead sponsor of the planned Dragon special purpose acquisition company, pursuing a listing on AIM Italia. Per the...
JAGX stock is on the move today after the popular company announced it had signed a memorandum of understanding for a SPAC deal. The post JAGX Stock: What to Know as SPAC News Sends Jaguar Health Soarin...
JAGX stock holders must weigh the impact of an intriguing European SPAC and a potential treatment option for Covid-19 long-haul patients. The post Hold Jaguar Health Stock for SPAC Spin-Off and Covid-19...
The 12-month, 300% gain with JAGX stock has a lot of headline news. There's a lot to like, but will Jaguar be able to build on its gains?
Likely, no one would suggest that JAGX stock is a fundamentally sound investment. But the current market environment makes shares a compelling short-term trade.
Jaguar Health stock is a speculative investment at best. JAGX stock is hard to nail down as it's hard to understand its numerous and strange financings.
Jaguar Health might merge part of its Napo Pharmaceuticals unit with a SPAC. What's this mean for JAGX stock over the long haul?
JAGX stock may be slumping today, but new SPAC merger news could turn things around. Here is what you should know about the Napo EU deal now.
If you've been sitting on the sidelines when it comes to JAGX stock, an important meeting should give you the excuse you've been waiting for. The post Proposed SPAC Merger Makes Jaguar Health Stock Intr...
Jaguar Health is showing better vital signs lately. However, there are still some things to consider before pouncing on JAGX stock.
Jaguar Health (JAGX) stock is on the rise Thursday after announcing a meeting concerning an upcoming SPAC merger in Italy. The post JAGX Stock Surges Ahead of Jaguar Health SPAC Merger Meeting appeared ...
If the first week of 2021 is the sign of things to come this year, traders and investors are going to make a lot of money. 4 NASDAQ stocks that really lit up the first week of 2021 were Ideanomics (NASD...
SAN FRANCISCO, CA / ACCESSWIRE / January 15, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today provided the replay link for the Company's January 14, 2021 investor webcast and a...
Regeneron Pharmaceuticals (NASDAQ: REGN) shares are trading higher after the company announced an additional U.S. order to purchase 1.25 million doses of its COVID-19 antibody cocktail bringing the tota...
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted...
SAN FRANCISCO, CA / ACCESSWIRE / January 13, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced it has entered into a securities purchase agreement with two institution...
If you believe in the future of plant-based medical treatments, then a long position in JAGX stock could offer exposure to this technology. The post Don't Try to Tame Jaguar Health Stock As It Rips High...
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
The developer of plant-based medicines has a promising drug pipeline.
JAGX stock is on the move today as Jaguar Health continues to gain attention. Here's what you should know about the biopharma play now.
Lechlemer development focused on possible tropical disease priority review voucher SAN FRANCISCO, CA / ACCESSWIRE / January 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announ...
Shares of Jaguar Health Inc., a developer of plant-based medicines for people and animals, soared more than 40% on Tuesday in heavy volume, extending their recent strong gains and putting the stock on t...
JAGX shares are once again on the move this week. Here's what you should know about the maker of the antidiarrheal treatment Mytesi.
JAGX stock is up on news that Jaguar Health just signed a royalty deal that will allow the company to pursue new FDA approvals. The post JAGX Stock: Why Jaguar Health Shares Are Surging 150% Today appea...
About JAGX
Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-rel... [Read more...]
| Industry Biotechnology | Founded 2013 |
| CEO Lisa Conte | Employees 34 |
| Stock Exchange NASDAQ | Ticker Symbol JAGX |
Financial Performance
In 2020, Jaguar Health's revenue was $9.39 million, an increase of 62.51% compared to the previous year's $5.78 million. Losses were -$33.81 million, -12.27% less than in 2019.